Ikena Oncology Stock Performance
| IKNA Stock | USD 1.31 0.01 0.77% |
The company retains a Market Volatility (i.e., Beta) of 0.43, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Ikena Oncology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ikena Oncology is expected to be smaller as well. At this point, Ikena Oncology has a negative expected return of -0.38%. Please make sure to check out Ikena Oncology's skewness, day typical price, and the relationship between the maximum drawdown and daily balance of power , to decide if Ikena Oncology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Ikena Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Ikena Oncologys Neutral Rating Reaffirmed at Wedbush | 12/24/2024 |
2 | Ikena Oncology Moves to Buy Rationale Behind the Upgrade - MSN | 12/31/2024 |
3 | Acquisition by Orbimed Advisors Llc of 353192 shares of Ikena Oncology subject to Rule 16b-3 | 01/17/2025 |
4 | Acquisition by Zhang Xiaoyan Michelle of 964 shares of Ikena Oncology at 2.1462 subject to Rule 16b-3 | 01/30/2025 |
5 | Discovering February 2025s Promising Penny Stocks On US Exchanges - Simply Wall St | 02/14/2025 |
6 | Disposition of 964 shares by Zhang Xiaoyan Michelle of Ikena Oncology at 12.0 subject to Rule 16b-3 | 03/14/2025 |
| Begin Period Cash Flow | 121.2 M |
Ikena |
Ikena Oncology Relative Risk vs. Return Landscape
If you would invest 167.00 in Ikena Oncology on December 21, 2024 and sell it today you would lose (36.00) from holding Ikena Oncology or give up 21.56% of portfolio value over 90 days. Ikena Oncology is currently does not generate positive expected returns and assumes 2.4352% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Ikena, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ikena Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ikena Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ikena Oncology, and traders can use it to determine the average amount a Ikena Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1566
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IKNA |
Estimated Market Risk
| 2.44 actual daily | 21 79% of assets are more volatile |
Expected Return
| -0.38 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ikena Oncology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ikena Oncology by adding Ikena Oncology to a well-diversified portfolio.
Ikena Oncology Fundamentals Growth
Ikena Stock prices reflect investors' perceptions of the future prospects and financial health of Ikena Oncology, and Ikena Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ikena Stock performance.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | (54.13 M) | ||||
| Shares Outstanding | 48.26 M | ||||
| Price To Earning | 3.89 X | ||||
| Price To Book | 0.50 X | ||||
| Price To Sales | 43.56 X | ||||
| Gross Profit | (30.88 M) | ||||
| EBITDA | (58.97 M) | ||||
| Net Income | (49.23 M) | ||||
| Cash And Equivalents | 192.81 M | ||||
| Cash Per Share | 5.32 X | ||||
| Total Debt | 7.52 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 6.98 X | ||||
| Book Value Per Share | 2.61 X | ||||
| Cash Flow From Operations | (46 M) | ||||
| Earnings Per Share | (1.02) X | ||||
| Market Capitalization | 62.74 M | ||||
| Total Asset | 141.51 M | ||||
| Retained Earnings | (331.62 M) | ||||
| Working Capital | 116.39 M | ||||
About Ikena Oncology Performance
By analyzing Ikena Oncology's fundamental ratios, stakeholders can gain valuable insights into Ikena Oncology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ikena Oncology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ikena Oncology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.45) | (0.47) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | (0.39) | (0.37) |
Things to note about Ikena Oncology performance evaluation
Checking the ongoing alerts about Ikena Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ikena Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ikena Oncology generated a negative expected return over the last 90 days | |
| Ikena Oncology may become a speculative penny stock | |
| Ikena Oncology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (49.23 M) with loss before overhead, payroll, taxes, and interest of (30.88 M). | |
| Ikena Oncology currently holds about 192.81 M in cash with (46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 964 shares by Zhang Xiaoyan Michelle of Ikena Oncology at 12.0 subject to Rule 16b-3 |
- Analyzing Ikena Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ikena Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Ikena Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ikena Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ikena Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ikena Oncology's stock. These opinions can provide insight into Ikena Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ikena Stock analysis
When running Ikena Oncology's price analysis, check to measure Ikena Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ikena Oncology is operating at the current time. Most of Ikena Oncology's value examination focuses on studying past and present price action to predict the probability of Ikena Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ikena Oncology's price. Additionally, you may evaluate how the addition of Ikena Oncology to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |